Keck School of Medicine of USC

 Zilkha

2016 Zilkha Neurogenetic Institute Annual Report

January 6th, 2017|

The Zilkha Neurogenetic Institute has released its 2016 annual report. Click here to read the report.

Keck faculty among the world’s most influential researchers

December 16th, 2016|

Sir Isaac Newton once referred to the process of discovery as “standing on the shoulders of giants,” meaning that revolutionary science and innovation is built on the work of previous researchers. Some researchers are more impactful than others. One measure of this is the number of times a particular researcher’s work is cited, thus serving

Zlokovic receives nearly $25 million to study Alzheimer’s disease

October 21st, 2016|

Berislav Zlokovic, MD, PhD, a pioneer of the theory that fixing the brain’s leaky blood vessels will prevent Alzheimer’s disease, has received four grants totaling up to $24.9 million over five years.

The funding allows Zlokovic, director of the Zilkha Neurogenetic Institute, to attack from different fronts the blood-brain barrier, a gatekeeper that prevents toxic substances

Hope for reversing stroke-induced long-term disability

August 22nd, 2016|

A human protein combined with stem cell therapy has been found to repair stroke damage to the brain, according to a new USC-led study on mice.

Permanent brain damage from a stroke may be reversible thanks to a developing therapeutic technique, a USC-led study has found.

The novel approach combines transplanted human stem cells with a special

Study: Flu-like symptoms in pregnant woman could affect baby

June 22nd, 2016|

Babies born to mothers whose immune systems had to grapple with a viral assault — even a mild one — have increased risk of brain and central nervous system abnormalities, according to a new study.

A USC-led team of researchers examined how the immune systems of pregnant mice (roughly equivalent to human mothers in their first

Symposium examines state of Alzheimer’s disease research

June 3rd, 2016|

Several of the world’s foremost neurology and neuroscience experts gathered recently to discuss the state of Alzheimer’s disease research at the third annual Zilkha Symposium on Alzheimer Disease and Related Disorders.

Titled “Bench to Bedside and Beyond: Relating Discovery Research to Translational Developments and Clinical Efforts,” the symposium was held April 15 at the Zilkha Neurogenetic

ZNI hosted the 3rd Annual international Zilkha Symposium on Alzheimer Disease and Related Disorders

May 4th, 2016|

The third annual Zilkha Symposium on April 15, 2015 brought together scientists from the United States and Europe to discuss the complexities of Alzheimer’s disease. Alzforum, a news website dedicated to helping researchers accelerate Alzheimer’s disease and related disorders research, covered the event. Click here to read the three article series and event coverage.

USC announces six honorary degree recipients for 2016 commencement

May 2nd, 2016|

USC will recognize six honorary degree candidates for their contributions to the community as civic, academic and arts leaders as part of USC’s 133rd commencement ceremony at the University Park Campus on May 13.

The recipients are two-time Academy Award-winning filmmaker Alejandro G. Iñárritu; Mark Stevens ’81, MS ’84 and Mary Stevens; renewable energy company founder

Opera singers come to campus for Visions and Voices event

April 26th, 2016|

Attendees were treated to several operatic performances and a discussion about the ways music affects the mind during “Music and Medicine: Experiments and Explorations,” a Visions and Voices event held March 31 at Mayer Auditorium on the Health Sciences Campus.

Berislav Zlokovic, MD, PhD, director of the Zilkha Neurogenetic Institute and professor and chair of the

USC Norris scientists work to unravel the genetics of colorectal cancer

April 15th, 2016|

In the decades-long search for answers, cancer researchers have been taking small steps toward solving some of the puzzles that perplex modern physicians.

Why do some patients respond better to some medicines, while others require a different course of treatment? What age should be recommended for the public to get screened for certain cancers?

While many of